Best Hospitals for Salivary Gland Cancer Treatment in Dubai, UAE

Salivary gland cancers are a heterogeneous group of epithelial malignancies arising in the parotid (70–80% of cases), submandibular, sublingual, or minor salivary glands distributed throughout the oral cavity, oropharynx, and sinonasal tract. The WHO Classification of Head and Neck Tumours (2022) recognises more than 20 distinct histological subtypes — including mucoepidermoid carcinoma (the most common), adenoid cystic carcinoma (notable for perineural invasion and late distant metastasis), acinic cell carcinoma, secretory carcinoma (characterised by ETV6-NTRK3 fusion), salivary duct carcinoma, and carcinoma ex pleomorphic adenoma. Tumour grade (low, intermediate, high) is the single strongest predictor of behaviour: low-grade lesions are frequently cured with surgery alone, whereas high-grade tumours carry a significant risk of regional nodal spread, distant metastasis to lung, bone, or liver, and require multimodal therapy.

• Newly diagnosed or recurrent primary salivary gland malignancy confirmed by core-needle or incisional biopsy with histopathological review
• Resectable disease (T1–T4a) in the parotid, submandibular, sublingual, or minor salivary glands where curative intent surgery is feasible
• Patients with high-grade histology (salivary duct carcinoma, carcinoma ex pleomorphic adenoma, high-grade mucoepidermoid) who require adjuvant IMRT ± systemic therapy
• Patients with locally advanced or recurrent disease being evaluated for re-irradiation, palliative surgery, or systemic therapy
• Individuals with molecularly characterised metastatic disease (HER2+, NTRK fusion, AR+, RET alteration) seeking targeted therapy protocols
• +1 more

Required Diagnostic Workup Before Travel:

• Contrast-enhanced MRI of the primary site (preferred over CT for soft-tissue and perineural invasion detail)
• CT chest, abdomen, and pelvis with contrast (staging, distant metastasis)
• FDG-PET/CT (recommended for high-grade histology, stage III–IV, or suspected recurrence)
• Core-needle biopsy pathology report with WHO histological subtype and grade; immunohistochemistry for S100, p63, SOX10, mammaglobin, GCDFP-15
• Molecular/genomic profiling panel (HER2 FISH/IHC, NTRK fusion testing by NGS or IHC, androgen receptor IHC, Ki-67 proliferation index)
• +5 more

Surgical Approaches

Parotidectomy (Superficial, Total, or Radical): The cornerstone of parotid salivary gland cancer management. Superficial parotidectomy (removal of the lobe lateral to the facial nerve) is performed for low-grade, laterally confined tumours with careful intraoperative facial nerve monitoring using continuous electromyographic (EMG) nerve monitoring systems. Total parotidectomy with facial nerve preservation is performed for deeper lobe involvement. Radical parotidectomy — sacrificing the facial nerve — is reserved for direct tumour invasion of the nerve, with immediate facial nerve reconstruction using the greater auricular nerve, sural nerve graft, or hypoglossal-to-facial anastomosis where feasible. Frozen-section margin analysis at the time of surgery is standard practice to achieve R0 (microscopically clear) resection.

Submandibular Gland Excision and Floor-of-Mouth Resection: For submandibular and sublingual primaries, en-bloc resection including the gland, capsule, and adjacent soft tissue is performed. Involvement of the mandible requires marginal or segmental mandibulectomy with microvascular free-flap reconstruction (fibula free flap, radial forearm free flap, anterolateral thigh flap) to restore form and function.

Neck Dissection: Selective neck dissection (levels I–III or I–IV) is standard for clinically or radiologically node-positive necks (cN+). Elective neck dissection is recommended for high-grade histology, T3/T4 tumours, or perineural/lymphovascular invasion even when the neck is clinically N0, given occult nodal metastasis rates of 20–49% in these scenarios. Modified radical neck dissection preserving the sternocleidomastoid, internal jugular vein, and accessory nerve is preferred over radical dissection.

PHASE 1 — REMOTE CONSULTATION AND PRE-TRAVEL PREPARATION (Weeks 1–2)

GAF Healthcare's oncology case managers receive your medical records digitally (MRI, PET-CT, biopsy reports, molecular panel). These are reviewed by the assigned head-and-neck surgical oncologist and submitted to the multidisciplinary tumour board (MDT) — comprising head-and-neck surgery, medical oncology, radiation oncology, pathology, radiology, speech therapy, and dentistry — for a virtual pre-consultation opinion. A detailed treatment plan and personalised cost estimate are issued within 48–72 hours. Medical visa application (India) or entry visa/visa-on-arrival process (UAE) is initiated simultaneously.

PHASE 2 — ARRIVAL AND IN-PERSON ASSESSMENT (Days 1–3 in Country)